Activity of OZ78 analogues against Fasciola hepatica and Echinostoma caproni
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID 1022809
Author(s) Kirchhofer, C.; Vargas, M.; Braissant, O.; Dong, Y.; Wang, X.; Vennerstrom, J. L.; Keiser, J.
Author(s) at UniBasel Kirchhofer, Carla
Keiser, Jennifer
Year 2011
Title Activity of OZ78 analogues against Fasciola hepatica and Echinostoma caproni
Journal Acta tropica : Zeitschrift für Tropenwissenschaften und Tropenmedizin
Volume 118
Number 1
Pages / Article-Number 56-62
Keywords Fasciola hepatica, Echinostoma caproni, Synthetic peroxides, In vivo studies, In vitro studies, Microcalorimetry
Abstract The rapid spread of triclabendazole resistance in veterinary medicine is an important motivation for fasciocidal drug discovery and development. The aim of this study was to characterize the fasciocidal properties of 1,2,4,5-tetraoxane (MT04 and MT14) and 1,2,4-trioxane (ST16 and ST28) analogues of the fasciocidal drug candidate OZ78, an 1,2,4-trioxolane. Dose response relationships were determined against juvenile and adult Fasciola hepatica in rats and Echinostoma caproni in mice. The temporal effects of MT04, MT14, ST16, and ST28 compared to OZ78 on the viability of F. hepatica were tested in vitro. The heat flow of OZ78 and MT04 treated flukes was studied with isothermal microcalorimetry. Finally, surface changes to adult flukes were monitored by scanning electron microscopy (SEM) 18, 24, and 48h post-treatment of rats with 50mg/kg MT04. Administration of 50-100mg/kg of the synthetic peroxides resulted in complete elimination of adult F. hepatica from rats. SEM pictures revealed sloughing and blebbing already 18h post-treatment with MT04. MT04 (100mg/kg) cured infections with juvenile F. hepatica, whereas MT14, ST16, and ST28 showed only low to moderate worm burden reductions. At 300mg/kg, MT14 was the only compound to completely eliminate worms from E. caproni infected mice. MT14 showed the highest activity against juvenile F. hepatica in vitro. MT04 was very active against adult F. hepatica in vitro, which was confirmed by heat flow measurements. In conclusion, we have identified MT04 as another lead compound with potential against F. hepatica, hence further preclinical studies are necessary to determine if MT04 can be considered a drug development candidate
Publisher Elsevier Science Publ.
ISSN/ISBN 0001-706X
Full Text on edoc Available
Digital Object Identifier DOI 10.1016/j.actatropica.2011.02.003
PubMed ID
ISI-Number WOS:000289399200009
Document type (ISI) Journal Article

MCSS v5.8 PRO. 0.449 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |